TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
Rhea-AI Summary
TG Therapeutics (NASDAQ:TGTX) announced that Chairman and CEO Michael S. Weiss will participate in the Jefferies Global Healthcare Conference at the Marriott Marquis in New York City, June 2-4, 2026.
A fireside chat is scheduled for Wednesday, June 3, 2026, at 11:40 AM ET, with a live webcast available on the company’s investor website Events page.
Positive
- None.
Negative
- None.
News Market Reaction – TGTX
In the May 28 session, TGTX declined 0.97%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 27 | Phase 3 results | Positive | -1.3% | Positive Phase 3 ENHANCE topline results for BRIUMVI in relapsing MS. |
| May 26 | Medical meeting data | Positive | +2.2% | Multiple BRIUMVI data presentations at the 2026 CMSC MS conference. |
| May 06 | Earnings and guidance | Positive | +16.3% | Strong Q1 2026 results, raised 2026 revenue guidance, and capital actions. |
| May 05 | Peer earnings | Positive | +1.1% | Precision BioSciences Q1 2026 update with cash runway and pipeline progress. |
| Apr 30 | Earnings call notice | Neutral | +0.6% | Scheduling of TG Therapeutics’ Q1 2026 earnings call and webcast details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent TG Therapeutics news, especially strong earnings and BRIUMVI updates, has more often led to positive price reactions, with the ENHANCE topline divergence standing out as an exception.
Over the last months, TG Therapeutics has reported strong BRIUMVI-driven financial results and multiple data updates. On May 6, 2026, raised guidance and solid Q1 numbers coincided with a 16.26% gain. Earlier, a May earnings call notice and CMSC data presentations had modest positive impacts. In contrast, the positive Phase 3 ENHANCE topline news on May 27, 2026 saw a -1.33% move, showing that even favorable clinical results have not always translated into near-term gains. Today’s conference participation fits into an ongoing cadence of investor and medical visibility events.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Fireside chat scheduled for Wednesday, June 3, 2026, at 11:40 AM ET
NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being held at the Marriott Marquis, in New York City on June 2-4, 2026. The fireside chat is scheduled to take place on Wednesday, June 3, 2026, at 11:40 AM ET.
A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at https://ir.tgtherapeutics.com/events.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
